NYSE · Drug Manufacturers - General · USD
Bristol-Myers Squibb Company (BMY) Stock Analysis
Bristol-Myers Squibb Company (BMY) is a Drug Manufacturers - General stock listed on NYSE and quoted in US Dollar.
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
BMY Key Statistics
As of Sep 4, 2026Trading
- Open
- $67.24
- Previous Close
- $68.09
- Day's Range
- 66.58–67.72
- 52-Week Range
- 42.52–68.64
- Volume
- 4.83M
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 0.23
Valuation
- Market Cap
- $136.49B
- P/E Ratio
- 14.98
- Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
- 10.19
- PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
- 2.54
- P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
- 2.78
- EPS (ttm)Profit attributable to each share over the last twelve months.
- 4.46
Financials (FY)
- Revenue (FY)
- $48.20B−0.22%
- Net Income (FY)
- $7.05B
- Profit marginThe share of revenue left as profit after all costs and taxes.
- 18.87%
- Shares Outstanding
- 2.04B
- 1-Year Return
- +49.98%
Dividend and dates
- Dividend
- $2.52+3.77%
- Ex-Dividend Date
- July 2, 2026
- Earnings Date
- October 29, 2026
- Avg Volume
- 11.50M
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
BMY Stock Return by Calendar Year
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | +28.06% |
| 2025 | +0.11% |
| 2024 | +15.81% |
| 2023 | −26.14% |
| 2022 | +18.98% |
| 2021 | +2.88% |
| 2020 | +0.41% |
| 2019 | +27.74% |
| 2018 | −12.90% |
| 2017 | +7.71% |
| 2016 (partial year) | −2.41% |
As of September 4, 2026.
BMY Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $48.20B | $7.05B | 14.6% |
| 2024 | $48.30B | −$8.95B | −18.5% |
| 2023 | $45.01B | $8.03B | 17.8% |
| 2022 | $46.16B | $6.33B | 13.7% |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $48.20B | $34.26B | $13.72B | $7.05B | 14.6% |
| 2024 | $48.30B | $34.33B | $5.89B | −$8.95B | −18.5% |
| 2023 | $45.01B | $34.31B | $8.20B | $8.03B | 17.8% |
| 2022 | $46.16B | $36.02B | $9.10B | $6.33B | 13.7% |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
BMY Dividend History
Dividends per share, 2025 · 4 payments
| Year | Dividends per share | Payments | Change |
|---|---|---|---|
| 2026* | $1.89 | 3 | — |
| 2025 | $2.48 | 4 | +3.3% |
| 2024 | $2.40 | 4 | +5.3% |
| 2023 | $2.28 | 4 | +5.6% |
| Year | Dividends per share | Payments | Change |
|---|---|---|---|
| 2026 (partial year) | $1.89 | 3 | — |
| 2025 | $2.48 | 4 | +3.3% |
| 2024 | $2.40 | 4 | +5.3% |
| 2023 | $2.28 | 4 | +5.6% |
| 2022 | $2.16 | 4 | +46.9% |
| 2021 | $1.47 | 3 | −35.8% |
| 2020 | $2.29 | 5 | +39.6% |
| 2019 | $1.64 | 4 | +2.5% |
| 2018 | $1.60 | 4 | +2.6% |
| 2017 | $1.56 | 4 | +310.5% |
| 2016 | $0.38 | 1 | — |
Most recent payment: $0.63 per share, ex-dividend July 2, 2026. Per-share amounts summed by calendar year from ex-dividend dates. Partial years are shown muted and marked with an asterisk.
BMY Valuation vs Drug Manufacturers - General Median
Median of 21 stocks| Metric | BMY | Drug Manufacturers - General median | vs median |
|---|---|---|---|
| P/E | 14.98 | 24.69 | 39% below |
| P/S ratio | 2.78 | 3.13 | 11% below |
| Profit margin | 18.87% | 8.09% | 10.8 pts above |
Medians across 21 Drug Manufacturers - General stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.
Recent News
Bristol-Myers Squibb (NYSE:BMY) Flashes Strong Technical Breakout Setup
ChartMillWhy Bristol Myers Squibb (BMY) Dipped More Than Broader Market Today
YahooBristol-Myers Squibb Stock: Is BMY Outperforming the Healthcare Sector?
YahooWhat Does Bristol Myers Squibb (BMY) Trial Pause Mean For Its Pipeline?
YahooBristol Myers Squibb (BMY) Gains On Camzyos Data, Is The Upside Already Priced In?
YahooBranded Pharmaceuticals Stocks Q2 Teardown: Bristol-Myers Squibb (NYSE:BMY) Vs The Rest
Yahoo
All 20 articles ↓Show fewer ↑
3 Reasons to Sell BMY and 1 Stock to Buy Instead
YahooBristol Myers Squibb (BMY) Stock Looks Reasonable On Earnings Yet Strong Returns Test Value
YahooCan Atrium Therapeutics (RNA)’s $15 Million Milestone From Bristol-Myers Squibb (BMY) Validate its RNA Platform?
YahooBristol-Myers Squibb (BMY)’s Cellares Exit Raises Questions Over Breyanzi Growth
YahooNew FDA Approval Gives Bristol-Myers Squibb (BMY) Another Potential Oncology Growth Catalyst
YahooBristol-Myers Squibb (BMY) Bets $2.3 Billion on Texas While Eli Lilly (LLY) Wins in the UK
YahooWhat Could Bristol Myers Squibb (BMY) AI Antibody Deal Mean For Drug Discovery?
YahooTurn Bristol-Myers Squibb into an Income Machine with This Options Play
YahooAstraZeneca Vs. Bristol-Myers Squibb: Who's The Better Bargain For Investors?
SeekingAlphaBristol-Myers Squibb Receives FDA Approval For ZENBEXUS In Combination With Daratumumab And Hyaluronidase-fihj and Dexamethasone For Patients with Multiple Myeloma
BenzingaCytokinetics Files Delaware U.S. District Court Claim Against Bristol-Myers Squibb And MyoKardia Seeking Judgment That CYTK Isn't Infringing U.S. Patent No. 12,616,697 And That The ’697 Patent Claims Are Invalid
BenzingaIs BMY's Growth Portfolio Strong Enough to Offset Legacy Drug Declines?
YahooIs Bristol Myers’ US$2.3 Billion Houston Manufacturing Campus Altering The Investment Case For BMY?
YahooAstraZeneca PLC (AZN) vs. Bristol-Myers Squibb Company (BMY): Wall Street Doesn’t Buy This Merger Talk
Yahoo
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.
Related Drug Manufacturers - General Stocks
Eli Lilly and Company
$1.02T
JNJJohnson & Johnson
$663.28B
ABBVAbbVie Inc.
$453.19B
MRKMerck & Co., Inc.
$370.89B
NVSNovartis AG
$304.10B
AZNAstraZeneca PLC
$252.33B
Popular Healthcare Stocks
UnitedHealth Group Incorporated
$356.47B
AMGNAmgen Inc.
$236.38B
TMOThermo Fisher Scientific Inc.
$226.94B
NVONovo Nordisk A/S
$206.02B
ABTAbbott Laboratories
$187.45B